Arcus Biosciences price target raised to $32 from $28 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Arcus Biosciences (RCUS) to $32 from $28 and keeps a Buy rating on the shares. The firm updated its model to remove domvanalimab revenues in non-small cell lung cancer and gastrointestinal cancers as it now believes the odds of success for these are 0%, but it simultaneously increased its revenue estimates for casdatifan in second-line clear cell renal cell carcinoma based on highly positive monotherapy data, the analyst tells investors.